Pharmosa Biopharm Inc.

Minutes of the 2026 First Extraordinary General Meeting

Type：Physical Meeting

Time：Thursday, January 8, 2026, at 10:00 a.m.

Location：Room 3 & 4,1st Floor, No. 508, Section 7, Zhongxiao East Road, Nangang District, Taipei City (Taipei Bioinnovation Park)

Total shares represented by shareholders present in person or by proxy：A total of 77,061,582 shares were represented (including 58,045,115 shares voted electronically) , accounting for 59.66% of total shares outstanding of 129,152,804 shares

Attending Directors：Chien-Chih Wang (Representative of FENGSI Investment Co., Ltd.), Chairman ； Lin-Chiuan Yan (Representative of FUKESHE Investment Co., Ltd.), Vice Chairman；Pei Kan, Director

Attendance：Shu-Ping Yang, CFO

Chairman：Chien-Chih Wang　　Recording Secretary：Shu-Ping Yang

i、Calling of Meeting to Order：The aggregate shareholding of the shareholders present or by proxy constituted a quorum. The Chairman called the meeting for order.

ii、Chairman’s Remarks：omitted.

iii、Matters for Discussion

1. The Amendment of Articles of Incorporation
2. Lifting of non-competition restrictions for the Directors

iv、Extempore Motions

v、Adjournment

Matters for Discussion

Proposal No. 1

The Amendment of Articles of Incorporation

[Proposed by the Board of Directors]

Explanation：

1.To meet the Company's future business development needs, it is proposed to add new business items to accelerate the establishment of the Company's own manufacturing facility, reduce outsourcing production costs, and enhance operational efficiency.

2.As the addition of new business items involves changes to the Company's business scope, amendments to the Company's "Articles of Incorporation" are proposed. For the comparison table of the revised provisions, please refer to Attachment 1.

Resolution：The above proposal was ratified as proposed. The voting results are as follows：Total Voting Rights Represented at the Time of Voting 77,061,582 votes (including 58,045,115 votes cast via electronic voting)

Voting Result	Electronic Votes	Total Votes (Including Electronic Votes)	Percentage of Total Voting Rights Represented
Approved	55,774,231	74,166,222	96.24%
Opposed	106,604	106,604	0.14%
Invalid	0	0	0%
Abstained	2,164,280	2,788,756	3.62%

Proposal No. 2

Lifting of non-competition restrictions for the Directors

[Proposed by the Board of Directors]

Explanation：

1.According to Article 209 of the Company Act, “A director who does anything for himself or on behalf of another person that is within the scope of the company's business shall explain to the meeting of shareholders the essential contents of such an act and secure its approval.”

2.To leverage the expertise and relevant experience of the company's directors, we have requested shareholder approval to lift the non-competition restrictions on directors in accordance with the provisions of the Company Act.

3.Please refer to the following table：

Job title	Name	Other Position
Independent Director	Yen-Ling Fang	Independent Director of Jentech Precision Industrial Co., Ltd

Permitted Scope of Competitive Activities：Business activities similar to the company's scope of operations.

Permitted Duration of Competitive Activities： The period during which the individual serves as a director of the company.

Resolution：The above proposal was ratified as proposed. The voting results are as follows：Total Voting Rights Represented at the Time of Voting 77,061,582 votes (including 58,045,115 votes cast via electronic voting)

Voting Result	Electronic Votes	Total Votes (Including Electronic Votes)	Percentage of Total Voting Rights Represented
Approved	53,663,835	72,055,826	93.50%
Opposed	2,218,699	2,218,699	2.88%
Invalid	0	0	0%
Abstained	2,162,581	2,787,057	3.62%

Summary of Shareholder Remarks:

Shareholder (Account No. 9020) Raised the Following Questions：

Questions	Responses
1.Are there any new developments regarding the lifting of non-competition restrictions for directors?	Regarding the non-competition restrictions for independent directors, Independent Director Yen-Ling Fang has served two terms with the Company. Since she was newly appointed as an independent director of Jentech Precision Industrial Co., Ltd. last year, and the appointment was approved by the Board, the proposal to lift the restriction was scheduled for the nearest general meeting. Therefore, it is being presented for explanation at this Extraordinary General Meeting.
2.What is the status of the milestone payments and the expected timing of receipt?	Under the licensing partnership with Liquidia for L606, development milestone payments for the global Phase 3 clinical trial (RESPIRE) targeting PH-ILD (Pulmonary Hypertension associated with Interstitial Lung Disease) will be recognized based on the actual enrollment progress. The shipment of Phase 3 trial medication was completed last year, and relevant trial information has been registered on ClinicalTrials.gov. Regulatory procedures are progressing according to plan. Liquidia has completed the coordination with major global trial centers and relevant specialists. Furthermore, as the US is currently the only market with approved treatments for PH-ILD and there are no available drugs in other major markets, the Company remains cautiously optimistic about the enrollment progress.
3.What is the current status of L608?	For the L608 product development plan, the Company expects to submit the IND (Investigational New Drug) application to the US FDA in Q1 2026, with the First Patient In (FPI) expected in Q2. This pertains to the Phase II clinical trial plan in the US. Details regarding the second extension plan for L608 will be formally presented to the investing public at the next institutional investor briefing.
4.What is the	Regarding the establishment of internal production lines,

status of the pharmaceutical production line installation?	the filling plant located on the 11th floor of the Taipei Bioinnovation Park has largely completed the installation of the HVAC system and major machinery. The Company plans to complete equipment validation in Q1 2026 and initiate trial operations for test production in Q2. In conjunction with the amendment to the Articles of Incorporation approved at this meeting, the Company will formally submit applications to the competent authorities. The Company expects to apply for a site inspection by the Taiwan TFDA in the second half of 2026 and plans to invite the EU QP for inspection in 2027. Once the inspection processes are complete, the Company will be able to supply samples for Phase 3 trials in global markets and proceed directly to regulatory audits upon completion of clinical trials, thereby accelerating marketing approvals and completing the overall commercialization layout of the GMP plant.

Shareholder (Account No. 7645) Raised the Following Questions：

Questions	Responses
One of the four major goals at the 2025 Annual General Meeting was the recognition of milestone payments. It appears there is a delay; can these be recognized in Q1 2026?	Regarding the milestone payment originally scheduled for recognition at the end of last year, the initial timeline was estimated based on the development premise of using the Company's proprietary nebulizer. However, during the R&D process, the Company and its partner, Liquidia Corporation, conducted a comprehensive evaluation. To accelerate the execution of the global Phase III clinical trials and the subsequent New Drug Application (NDA) process, a strategic decision was made to prioritize the use of a nebulizer that has already received U.S. FDA 510(k) milestone payment have changed accordingly; therefore, the recognition timing will be deferred in alignment with the subsequent development schedule of the Company's proprietary nebulizer.

Extempore Motions : None.

Adjournment：10:23 AM, the Chairman adjourned the Meeting

(The minutes only outline the essentials of the proceedings; the content and procedures of the meeting are subject to the audiovisual recording at the meeting venue.)

Notice to Readers If there is any conflict between the English version and the original Chinese version or any difference in the interpretation of the two versions, the Chinese-language Meeting Minutes shall prevail.